IRD
Opus Genetics, Inc. NASDAQ Listed Jan 19, 2015$5.36
Mkt Cap $382.7M
52w Low $0.90
90.8% of range
52w High $5.81
50d MA $4.89
200d MA $2.68
P/E (TTM)
-6.4x
EV/EBITDA
-31.2x
P/B
208.1x
Debt/Equity
0.0x
ROE
-323.1%
P/FCF
-35.5x
RSI (14)
—
ATR (14)
—
Beta
0.52
50d MA
$4.89
200d MA
$2.68
Avg Volume
966.6K
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
37000 Grand River Avenue · Durham, MI 48335 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | TNS | -0.11 | -0.14 | -27.3% | 4.85 | +3.1% | +3.3% | -3.4% | +3.9% | +3.2% | -7.5% | — |
| Nov 12, 2025 | TNS | -0.14 | -0.12 | +14.3% | 1.92 | +2.1% | -3.6% | +1.6% | -7.4% | +8.0% | -1.1% | — |
| Aug 13, 2025 | TNS | -0.25 | -0.12 | +52.0% | 1.10 | -4.5% | +7.3% | +1.7% | -4.2% | -3.5% | +4.5% | — |
| May 15, 2025 | TNS | -0.34 | -0.32 | +5.9% | 0.95 | -1.1% | +7.4% | -1.0% | -1.6% | +2.6% | -1.0% | — |
| Mar 31, 2025 | TNS | -0.34 | -1.27 | -273.5% | 0.98 | +0.4% | -7.3% | +2.5% | +5.1% | -9.6% | -4.5% | — |
| Nov 12, 2024 | TNS | -0.30 | -0.29 | +3.3% | 1.14 | +0.9% | -5.3% | -1.9% | +0.0% | -14.0% | -3.0% | — |
| Aug 13, 2024 | TNS | -0.25 | -0.30 | -20.0% | — | — | — | — | — | — | — | — |
| May 10, 2024 | TNS | -0.18 | -0.29 | -61.1% | — | — | — | — | — | — | — | — |
| Mar 9, 2024 | TNS | -0.05 | -0.22 | -315.2% | — | — | — | — | — | — | — | — |
| Nov 13, 2023 | TNS | -0.22 | 0.25 | +211.8% | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | TNS | -0.23 | -0.24 | -4.7% | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | TNS | -0.15 | -0.28 | -79.6% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Citizens | Initiates | Mkt Perform | $12 | $5.12 | $5.09 | -0.6% | -2.3% | -6.6% | +9.4% | +0.6% | +1.6% |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $5.01 | $5.05 | +0.8% | -3.4% | +3.9% | +3.2% | -7.5% | -2.9% |
| Mar 12 | Chardan Capital | Maintains | Buy → Buy | — | $5.01 | $5.05 | +0.8% | -3.4% | +3.9% | +3.2% | -7.5% | -2.9% |
| Mar 2 | BTIG | Maintains | Buy → Buy | — | $4.16 | $4.08 | -1.9% | +4.1% | -1.8% | +7.5% | +4.4% | +2.5% |
| Jan 28 | BTIG | Maintains | Buy → Buy | — | $2.83 | $2.84 | +0.4% | -4.6% | -7.4% | -7.6% | +0.4% | +3.4% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $1.92 | $1.96 | +2.1% | -3.6% | +1.6% | -7.4% | +8.0% | -1.1% |
| Nov 7 | Chardan Capital | Maintains | Buy → Buy | — | $2.03 | $2.04 | +0.5% | -1.5% | -1.5% | +0.0% | -2.5% | -3.6% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.02 | $1.02 | +0.0% | -4.3% | -3.5% | -0.2% | +5.3% | +1.0% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.98 | $0.99 | +0.4% | -7.3% | +2.5% | +5.1% | -9.6% | -4.5% |
| Apr 1 | Jones Trading | Maintains | Buy → Buy | — | $0.98 | $0.99 | +0.4% | -7.3% | +2.5% | +5.1% | -9.6% | -4.5% |
| Feb 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.10 | $1.13 | +2.7% | +1.8% | -0.9% | -0.9% | -1.8% | -3.7% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.20 | $1.14 | -5.0% | -7.5% | -8.1% | -2.0% | -8.8% | -9.0% |
| Oct 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.33 | $1.33 | +0.0% | -12.0% | -3.4% | +3.5% | +15.4% | -1.5% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 14 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 13 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | Sell | 7,542 | $5.19 | $39K | 509,233 | -2.34% | +1.56% |
| Apr 23, 2026 | Gagnon Robert E. | Chief Financial Officer | Sell | 7,842 | $5.18 | $41K | 592,158 | -2.34% | +1.56% |
| Apr 23, 2026 | SCHACHLE JOSEPH K | Chief Operating Officer | Sell | 4,697 | $5.22 | $25K | 296,084 | -2.34% | +1.56% |
| Apr 23, 2026 | YERXA BENJAMIN R | President | Sell | 7,470 | $5.24 | $39K | 711,535 | -2.34% | +1.56% |
| Apr 23, 2026 | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | Sell | 1,641 | $5.20 | $9K | 188,671 | -2.34% | +1.56% |
| Apr 23, 2026 | Magrath George | Chief Executive Officer | Sell | 9,511 | $5.22 | $50K | 1,741,344 | -2.34% | +1.56% |
8-K · 2.02
!! High
Opus Genetics, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 2.03
! Medium
Opus Genetics, Inc. -- 8-K 2.03: Credit Facility
Opus Genetics (IRD) secured senior secured notes financing from OPCM SA LLC and other purchasers, creating a new debt obligation to fund operations and growth initiatives.
Apr 24
8-K
Opus Genetics, Inc. -- 8-K Filing
I appreciate the request, but I cannot write a meaningful sentence based on this summary. The provided text only describes filing mechanics rather than substantive business news, material events, or deal outcomes that would impact investors.
Apr 22
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
George Magrath's appointment as CEO at Ishares Trust (IRD) signals potential strategic direction shifts; investors should monitor whether new leadership drives operational improvements or signals underlying governance concerns.
Apr 7
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
IRD secured new financing from OPCM SA LLC, which likely provides capital for operations or growth but investors should monitor debt terms and repayment obligations that could dilute shareholders or constrain future flexibility.
Apr 7
8-K
Unknown — 8-K Filing
Opus Genetics advancing its clinical-stage gene therapy pipeline with consistent milestone progress, though pre-revenue status means stock value depends entirely on upcoming trial data success and funding runway.
Mar 10
8-K · 8.01
!! High
Opus Genetics, Inc. -- 8-K 8.01: Material Event / Announcement
Opus Genetics announced a material event that could significantly impact investor returns, but specific details require reviewing the full filing to assess whether this represents positive news, regulatory action, or strategic changes affecting stock valuation.
Feb 19
Data updated apr 25, 2026 4:12pm
· Source: massive.com